Silence Therapeutics plc “Capital Markets Event on Tuesday 14 November”

Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that the Company will host a Capital Markets event for investors, analysts and media at ME London Hotel, Strand, London WC2R 1HA on Tuesday 14 November between 3:00pm and 5:30pm GMT.

At the meeting, Silence will provide an update on its RNAi pipeline and proprietary technology platforms, as well as a review of the Company’s strategy. Further details will follow in due course.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Silence Therapeutics plc

    More articles like this

    Silence Therapeutics plc

    Silence Therapeutics analyst presentation 6th March

    Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended

    Silence Therapeutics plc

    A further European patent for Silence Therapeutics plc

    Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent

    Silence Therapeutics plc

    Silence Therapeutics Notice of Interim Results

    Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six